Wall Street’s appetite for weight-loss drug stocks over the past four years has powered Eli Lilly & Co. to consistently trade above $1,000 per share. Now, some see the pharma giant’s stock as primed for a split.
Wall Street’s appetite for weight-loss drug stocks over the past four years has powered Eli Lilly & Co. to consistently trade above $1,000 per share. Now, some see the pharma giant’s stock as primed for a split.
<iframe src="https://statesidedaily.com/embed/cluster/a060a6e47d53ed82066214314a5464f73a95999f" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Eli Lilly Ripe for Stock Split After Obesity Drug-Fueled Rally"></iframe>
